Goliath Pharmaceuticals has teamed up with Galmed to expand the NASH pipeline.

ASC41 is an oral thyroid hormone-infested (THR-thyroid) astrogen, and its application for a clinical trial of NASH adaptation has recently been approved by China's State Drug Administration.
expects to have topline data on phase I safety, pharmacy and preliminary efficacy (LDL-C) in healthy volunteers with LDL-C greater than 110mg/dL by the end of 2020.
ASC41 selectively activates THR-thybosis to improve fat degeneration/lipotoxicity, inflammation, balloon sample changes and fibrosis in a direct and indirect manner.
In two NASH animal models, ASC41 improved liver fatty degeneration, inflammation and fibrosis to the same extent under the conditions of Resmetirom (i.e., MGL-3196, another THR-astrative in the clinical phase III.
Aramchol is a new type of synthetic small molecule that is a conjugate of bile acid and peanut acid connected by a stable group of alamide.
Aramchol plays its role in anti-hepatic cell fat degeneration and anti-fibrosis by inhibiting the expression of SCD 1 in liver cells and hepatocellular cells (HSCs).
in liver cells, the decrease in SCD 1 leads to an increase in the proportion of AMPK, FA oxidation and glutathione.
in HSC, inhibition of SCD 1 leads to an increase in the specificity of PPAR gamma, thereby preventing collagen production.
in phase NASHII. clinical trials, Aramchol has significantly reduced liver fat and improved liver tissue, including balloon-like and fibrosis, as well as liver bio-chemical and blood sugar indicators, with good safety and tolerance.
Aramchol is currently conducting a Phase III Registration Study (ARMOR) for the treatment of NASH and liver fibrosis and has been granted fast-track status by the U.S. Food and Drug Administration to treat NASH.
.